KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic): 2009-2025

Historic EPS (Basic) for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $1.55.

  • Rigel Pharmaceuticals' EPS (Basic) rose 118.31% to $1.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.33, marking a year-over-year increase of 2652.17%. This contributed to the annual value of $0.99 for FY2024, which is 168.75% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EPS (Basic) is $1.55, which was down 53.45% from $3.33 recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' EPS (Basic) peaked at $3.33 during Q2 2025, and registered a low of -$3.09 during Q4 2022.
  • For the 3-year period, Rigel Pharmaceuticals' EPS (Basic) averaged around $0.52, with its median value being $0.05 (2023).
  • In the last 5 years, Rigel Pharmaceuticals' EPS (Basic) crashed by 2,107.14% in 2022 and then spiked by 5,650.00% in 2025.
  • Rigel Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.14 in 2021, then slumped by 2,107.14% to -$3.09 in 2022, then skyrocketed by 101.62% to $0.05 in 2023, then spiked by 1,520.00% to $0.81 in 2024, then skyrocketed by 118.31% to $1.55 in 2025.
  • Its EPS (Basic) stands at $1.55 for Q3 2025, versus $3.33 for Q2 2025 and $0.64 for Q1 2025.